Navigation Links
Dengue Vaccine Initiative welcomes latest progress in vaccine development
Date:9/11/2012

WASHINGTON, D.C.September 11, 2012Today, The Dengue Vaccine Initiative (DVI) welcomed new clinical trial results that reveal progress in developing the first-ever dengue vaccine. In a publication in The Lancet, pharmaceutical company Sanofi Pasteur reported results from the first study conducted to evaluate the efficacy of any dengue vaccine candidate against clinical dengue disease in a population naturally exposed to dengue.

Dengue vaccine development efforts have been difficult because dengue is caused by four different related viruses, known as DENV 1, 2, 3 and 4. The results published in today's study found that Sanofi's vaccine candidate was effective against DENV 1, 3 and 4, but DENV 2 appeared to be resistant to vaccine in this trial. The vaccine candidate, called CYD-TDV, was tested on a group of 4,002 schoolchildren in Thailand, where dengue is known to be endemic.

"While there is still much work to be done, these clinical trials mark a decisive step forward in the development of a safe and effective vaccine," said Dr. Luiz da Silva, Director of the Dengue Vaccine Initiative. "We support the progress made by Sanofi Pasteur as well as efforts by other organizations to deliver a vaccine to populations in endemic countries."

There is no vaccine available to treat or prevent dengue fever. While vaccines have been under development since the 1940s, little progress had been made until recently. Reported dengue cases have increased from an annual average of fewer than 300,000 cases during the 1980s to nearly 1 million per annum from 2000 to 2005.The WHO estimates that there are 50 to 100 million dengue infections a year.

"This is a dramatic increase in dengue incidence rates, and yet it's very likely that the numbers still do not reflect the full scope of the problem," said Dr. Ciro de Quadros, Executive Vice President of the Sabin Vaccine Institute. "An exact number is difficult to determine due to a lack of accurate diagnostic testing and common misdiagnosis."

Dengue is the most common mosquito-borne viral disease, with more than 2.5 billion people at risk for the disease globally, resulting in an estimated 21,000 deaths per year. Dengue symptoms can range from mild, flu-like symptoms to severe circulatory failure, coma and death. Most outbreaks occur during the rainy season in endemic countries like Thailand and Brazil, when mosquito populations are high.

Currently, there are several dengue vaccines in various stages of development, with four candidates, including Sanofi Pasteur's, in clinical trial stages. The results of this first study, a phase IIb clinical trial, are not yet sufficient to prove or disprove efficacy of CYD-TDV. However, Sanofi has already begun phase III studies among 31,000 children in Asia and Latin America. These studies will provide further information, including pivotal efficacy results and additional safety data.

"In addition to saving lives and reducing illness, a dengue fever vaccine, once introduced, will have significant positive impacts on the global economy," added Dr. Orin Levine, Executive Director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. "The cost of dengue fever in the Americas alone is estimated to be $2.1 billion annually, and the burden of lost wages and productivity, along with the cost of healthcare, takes a great toll in endemic countries across the globe."


'/>"/>
Contact: Johanna Harvey
johanna.harvey@sabin.org
202-621-1691
Sabin Vaccine Institute
Source:Eurekalert

Related medicine news :

1. Dengue Fever a Major Cost Burden in Puerto Rico
2. RV144 vaccine efficacy increased against certain HIV viruses
3. Too Few Girls Get HPV Vaccine Against Cancer: CDC
4. Cancer turns off important immune cells, complicating experimental vaccine therapies
5. UTMB receives $1.2 million to provide HPV vaccine
6. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
7. Kindergarten Vaccines Close to Target Levels: CDC
8. Dartmouth medical research closes in on new tuberculosis vaccine
9. Vaccine and autism debate masks real problem
10. NIH awards $7.8 million for innovative HIV vaccine approaches
11. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... PA (PRWEB) , ... November 30, 2016 , ... "I ... hand and arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I ... me to develop this handy device." , He developed the patent-pending DEFLECTOR to prevent ...
(Date:11/30/2016)... Gardens, FL (PRWEB) , ... November 30, 2016 ... ... eating disorder and mental health treatment has announced the opening of a new ... specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both males ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... have been a focus of public policymakers and system stakeholders in many states. ... released its Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) . ...
(Date:11/30/2016)... Austin, TX (PRWEB) , ... November 30, 2016 ... ... like to remind the clinical research community that the FDA Binding Guidance goes ... submit data in FDA-supported formats listed in the FDA Data Standards Catalog. The ...
(Date:11/30/2016)... ... 2016 , ... U.S. Security Associates (USA) announced the acquisition ... Richmond, Virginia. The acquisition further strengthens USA’s capabilities within the expanding healthcare ... prides itself on 100% client-retention to the healthcare industry. In addition, ODS has ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 Quantum Radiology,s Mobile Breast Center ... interpretation directly to women at the workplace, thereby maximizing ... as Delta Air Lines and SunTrust Bank, and community ... component of wellness initiatives. "I think it,s ... enables them to have a mammogram without taking a ...
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
Breaking Medicine Technology: